Inspire Announces Poster Presentations at 2008 Association for Research in Vision and Ophthalmology Annual Meeting
One poster presentation, "Evaluation of MMP2/9 Modulation by Azithromycin and DuraSite on Corneal Epithelial Cells in vitro," is related to AzaSite(R) (azithromycin ophthalmic solution) 1%, which is being studied in a series of Inspire-sponsored post-marketing clinical and non-clinical studies. This study provides preliminary data for exploring the effects of AzaSite on corneal wound healing.
-- J.L. Jacot, T.A. Jacot, J.D. Sheppard, Jr., F.A. Lattanzio, P.B. Williams, K. Brubaker
Monday, April 28, 2008, 11:15 am - 1:00 pm, Hall B/C, Program #1985 / Board #D1056
Two poster presentations are related to Inspire's novel glaucoma program. The first, "Topical Administration of Cytoskeletal Disrupting Agents Modulates Central Corneal Thickness, Pupil Diameter and Pupillary Light Response in the New Zealand White Rabbit" demonstrates that a number of previously studied cytoskeletal-active agents caused mild changes in resting static pupillary diameter and central corneal thickness, but had no effect on kinetic pupillary light responses, in pre-clinical testing.
-- R.S. Verhoeven, N. Kuney, C. Robinson, W.M. Peterson, J.L. Vittitow
Monday, April 28, 2008, 3:00 pm - 4:45 pm, Hall B/C, Program #2102/Board #A213
The second glaucoma-related poster, "Topical Administration of a Novel and Potent Rho Kinase (ROK) Inhibitor INS117548 Alters the Actin Cytoskeleton, Effectively Lowers IOP, and is Well Tolerated on the Ocular Surface," shows that INS117548, which is being developed by Inspire, reduced intraocular pressure (IOP) in animal models.
-- W.M. Peterson, J. Lampe, T. Navratil, Y. Paran, K. Zvi, E.A. Hennes, B.T. Gabelt, B. Geiger, P.L. Kaufman, J.L. Vittitow
Wednesday, April 30, 2008, 8:30 am - 10:15 am, Hall B/C, Program #3816/Board #A183
The fourth poster presentation, "Assessment of Antimuscarinic Activity of Topical and Oral Antihistamines," relates to a study in Inspire's ocular allergy program. The in vitro study was designed to assess whether the marketed antihistamines in the study had anticholinergic activity.
-- J.L. Boyer, K. Brubaker, S.C. Wolff, E.H. Fulcher, J.R. Lankford, T. Navratil
Tuesday, April 29, 2008, 3:00 pm - 4:45 pm, Hall B/C, Program #3616/Board #D949
The posters will be available on Inspire's website, www.inspirepharm.com, following the conference.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory and is developing products for dry eye, cystic fibrosis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
Inspire Pharmaceuticals, Inc.
Jenny Kobin, 919-941-9777, ext. 219
VP, Investor Relations and Corporate Communications
Dan Budwick, 212-477-9007, ext. 14
Posted: April 2008